Artios: Defining DNA Damage Response (DDR)-based therapeutics in cancer

*Published in our 2025 Meaningful Impact Report.

Artios has a pipeline of novel cancer therapies in development that target DNA Damage Response (DDR) pathways, to destroy certain cancers that are difficult to treat.

The company was founded in 2016 following IP Group’s initial investment, and formed by Cancer Research UK.

Patients suffering from certain cancers that are difficult to treat, who have limited other options available to them.

Artios aims to alleviate suffering, reduce mortality rates, enhance quality of life and potentially decrease healthcare costs associated with managing certain types of cancer.

Artios’ lead programme is in Phase 2 clinical trials for some types of cancer which are difficult to treat.

The Phase 2 study is focussed on treating a subtype of cancer called “ATM deficient tumours” and could help patients with colorectal (colon) and pancreatic cancer.

The current standard-of-care available to patients with these cancers is limited, and the 5-year survival rate can be very low (i.e. <10%). It is therefore estimated that Artios’ drug could help tens of thousands of patients each year and have a substantial impact on their quality and duration of life.

IP Group has supported Artios from preclinical studies through to the ongoing Phase 2 study that aims to demonstrate that its lead drug (ART0380) can effectively treat cancer.

In IP Group funded Phase 1/2a trials, ART0380 was shown to have clinical activity and durable responses across multiple cancer types.

IP Group has supported the company through investments from Series A to Series D and has held both Director and Observer roles on the Board.